The Claim
In patients with acute coronary syndrome after percutaneous coronary intervention, a PDCA cycle-based lipid-lowering strategy is associated with a 9.35-fold higher odds of achieving LDL-C goal attainment at 12 weeks, independent of statin use and ezetimibe therapy.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Among patients recovering from heart intervention procedures, a structured management approach called the PDCA cycle is linked to a 9.35 times higher likelihood of reaching recommended LDL cholesterol targets at 12 weeks, regardless of statin or ezetimibe use.
See the scientific wording
In patients with acute coronary syndrome after percutaneous coronary intervention, a PDCA cycle-based lipid-lowering strategy is associated with a 9.35-fold higher odds of achieving LDL-C goal attainment at 12 weeks, independent of statin use and ezetimibe therapy, suggesting the intervention itself contributes to improved outcomes beyond pharmacologic intensification.
When patients follow a strict, step-by-step plan to take their medicine and change their diet, their bodies clear cholesterol from the blood more efficiently because the liver increases its ability to pull LDL cholesterol out of circulation.
What the research says
1 studyPatients who followed a step-by-step plan to manage their cholesterol were nearly 10 times more likely to reach their target level, even when doctors gave them the same medicines as others. The plan itself made the difference.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.